Astrazeneca PLC (NYSE:AZN) shares saw unusually-high trading volume on Tuesday . Approximately 5,276,985 shares were traded during trading, a decline of 23% from the previous session’s volume of 6,868,391 shares.The stock last traded at $30.22 and had previously closed at $30.55.

AZN has been the subject of several research analyst reports. Bank of America Corp. reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Thursday, March 24th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Astrazeneca PLC in a report on Thursday, March 24th. Beaufort Securities reiterated a “hold” rating on shares of Astrazeneca PLC in a report on Thursday, March 31st. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Friday, April 1st. Finally, Goldman Sachs Group Inc. downgraded shares of Astrazeneca PLC from a “neutral” rating to a “sell” rating in a report on Monday, April 11th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $562.78.

The firm has a market cap of $76.66 billion and a P/E ratio of 26.35. The firm has a 50 day moving average price of $29.28 and a 200-day moving average price of $29.59.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Friday, April 29th. The company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by $0.09. During the same quarter in the previous year, the firm posted $1.08 EPS. The company had revenue of $6.12 billion for the quarter, compared to the consensus estimate of $5.96 billion. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. Equities research analysts expect that Astrazeneca PLC will post $2.36 earnings per share for the current fiscal year.

A number of institutional investors have modified their holdings of the company. Genesee Valley Trust Co. boosted its position in shares of Astrazeneca PLC by 5.4% in the fourth quarter. Genesee Valley Trust Co. now owns 31,627 shares of the company’s stock worth $1,074,000 after buying an additional 1,617 shares during the last quarter. Burney Co. boosted its position in shares of Astrazeneca PLC by 3.5% in the fourth quarter. Burney Co. now owns 130,492 shares of the company’s stock worth $4,448,000 after buying an additional 4,381 shares during the last quarter. Neuberger Berman Group LLC boosted its position in shares of Astrazeneca PLC by 5.7% in the fourth quarter. Neuberger Berman Group LLC now owns 100,709 shares of the company’s stock worth $3,419,000 after buying an additional 5,466 shares during the last quarter. Azimuth Capital Management LLC boosted its position in shares of Astrazeneca PLC by 6.7% in the fourth quarter. Azimuth Capital Management LLC now owns 88,203 shares of the company’s stock worth $2,994,000 after buying an additional 5,500 shares during the last quarter. Finally, Comerica Bank boosted its position in shares of Astrazeneca PLC by 5.4% in the fourth quarter. Comerica Bank now owns 139,827 shares of the company’s stock worth $4,442,000 after buying an additional 7,195 shares during the last quarter.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.